Pfizer shares slipped modestly in recent trading as investors continued to digest the company’s shrinking COVID-related revenue base and lingering legal uncertainty surrounding its flagship Comirnaty vaccine.
The stock ended Friday’s session at $25.68, marking a 1.42% decline for the second consecutive day, even as broader markets posted gains. The dip highlights growing investor sensitivity to Pfizer’s post-pandemic transition, where COVID-era blockbuster revenues are steadily fading.
Comirnaty sales fell sharply by nearly 59% in the latest quarter, underscoring how quickly pandemic demand has normalized. Paxlovid also continued to lose momentum, leaving Pfizer increasingly dependent on its non-COVID portfolio to stabilize earnings. While management has consistently emphasized diversification, the pace of decline in its COVID franchise remains a key overhang on sentiment.
Investor caution intensified following a Delaware federal court decision that dismissed an attempt to block GSK’s patent claims related to Pfizer and BioNTech’s COVID vaccine. The ruling did not determine whether Comirnaty infringes on GSK’s patents, but it left the broader legal dispute unresolved, adding another layer of uncertainty to an already declining franchise.
The case stems from ongoing intellectual property disputes tied to vaccine development technology. Although Pfizer is not immediately facing a final judgment, the lack of resolution means potential legal risks remain open-ended. For shareholders, this prolongs concerns over possible future liabilities or licensing costs tied to one of the company’s most high-profile products of the past five years.
With COVID revenues fading, Pfizer is increasingly relying on its pipeline in oncology, immunology, and obesity treatments to drive the next growth phase. CEO Albert Bourla has repeatedly pointed to these areas as central to the company’s long-term strategy, describing oncology and obesity drugs as key pillars for future leadership.
Recent developments include progress in cancer treatments, such as regulatory approval for new therapies targeting advanced breast cancer. However, investors remain cautious about timing, as many of Pfizer’s most promising pipeline assets are still years away from meaningful commercial impact.
For example, its obesity drug candidate, developed through recent acquisitions, is not expected to reach the market before 2028, leaving a notable gap in near-term growth drivers.
Despite operational challenges, Pfizer continues to lean on its strong dividend profile to maintain investor confidence. The company recently locked in its quarterly dividend of $0.43 per share, marking its 350th consecutive payout. This long-standing track record remains a key attraction for income-focused investors, even as capital appreciation prospects face pressure.
At the same time, Pfizer reported $14.5 billion in first-quarter revenue, representing modest operational growth. Excluding COVID-related products, revenue rose more strongly, suggesting underlying stability in the core business. Management reaffirmed its full-year outlook, projecting up to $62.5 billion in revenue and adjusted earnings of up to $3 per share.
The post Pfizer (PFE) Stock; Edges Lower as Investors Weigh Ongoing COVID Franchise Pressure appeared first on CoinCentral.
